Cargando…
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can e...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100212/ https://www.ncbi.nlm.nih.gov/pubmed/27821187 http://dx.doi.org/10.1186/s13045-016-0347-1 |
_version_ | 1782466094790868992 |
---|---|
author | Shimoni, Avichai Labopin, Myriam Savani, Bipin Volin, Liisa Ehninger, Gerhard Kuball, Jurgen Bunjes, Donald Schaap, Nicolaas Vigouroux, Stephane Bacigalupo, Andrea Veelken, Hendrik Sierra, Jorge Eder, Matthias Niederwieser, Dietger Mohty, Mohamad Nagler, Arnon |
author_facet | Shimoni, Avichai Labopin, Myriam Savani, Bipin Volin, Liisa Ehninger, Gerhard Kuball, Jurgen Bunjes, Donald Schaap, Nicolaas Vigouroux, Stephane Bacigalupo, Andrea Veelken, Hendrik Sierra, Jorge Eder, Matthias Niederwieser, Dietger Mohty, Mohamad Nagler, Arnon |
author_sort | Shimoni, Avichai |
collection | PubMed |
description | BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. METHODS: We analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥50 years, after SCT from HLA-matched siblings, during the years 1997–2005, median follow-up 8.3 years (0.1–17). RESULTS: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27–35) and 32 % (28–35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18–25) and 21 % (18–24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65–76) and 73 % (67–78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. CONCLUSIONS: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0347-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5100212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51002122016-11-08 Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation Shimoni, Avichai Labopin, Myriam Savani, Bipin Volin, Liisa Ehninger, Gerhard Kuball, Jurgen Bunjes, Donald Schaap, Nicolaas Vigouroux, Stephane Bacigalupo, Andrea Veelken, Hendrik Sierra, Jorge Eder, Matthias Niederwieser, Dietger Mohty, Mohamad Nagler, Arnon J Hematol Oncol Research BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. METHODS: We analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥50 years, after SCT from HLA-matched siblings, during the years 1997–2005, median follow-up 8.3 years (0.1–17). RESULTS: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27–35) and 32 % (28–35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18–25) and 21 % (18–24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65–76) and 73 % (67–78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. CONCLUSIONS: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0347-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-08 /pmc/articles/PMC5100212/ /pubmed/27821187 http://dx.doi.org/10.1186/s13045-016-0347-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Shimoni, Avichai Labopin, Myriam Savani, Bipin Volin, Liisa Ehninger, Gerhard Kuball, Jurgen Bunjes, Donald Schaap, Nicolaas Vigouroux, Stephane Bacigalupo, Andrea Veelken, Hendrik Sierra, Jorge Eder, Matthias Niederwieser, Dietger Mohty, Mohamad Nagler, Arnon Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title_full | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title_fullStr | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title_full_unstemmed | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title_short | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation |
title_sort | long-term survival and late events after allogeneic stem cell transplantation from hla-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of european group for blood and marrow transplantation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100212/ https://www.ncbi.nlm.nih.gov/pubmed/27821187 http://dx.doi.org/10.1186/s13045-016-0347-1 |
work_keys_str_mv | AT shimoniavichai longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT labopinmyriam longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT savanibipin longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT volinliisa longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT ehningergerhard longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT kuballjurgen longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT bunjesdonald longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT schaapnicolaas longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT vigourouxstephane longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT bacigalupoandrea longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT veelkenhendrik longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT sierrajorge longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT edermatthias longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT niederwieserdietger longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT mohtymohamad longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta AT naglerarnon longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta |